Close Menu
  • Business
  • World News
    • United States of America
    • Europe
    • Asia
    • Oceania
  • Technology
  • Sports
  • Money
  • Health
  • Life & Style
  • Shopping

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025
Facebook X (Twitter) Instagram
Daily News
Facebook X (Twitter) Instagram
Subscribe
  • Home
  • Business

    What Size Skip Do You Need for Your Project?

    May 12, 2025

    Introduction to Share CFDs: Understanding the Basics

    December 2, 2024

    Importance of Proper Disposal in Spray Foam Removal

    August 26, 2024

    The Underlying Dynamics of Italy’s Euro: Economic Policies and Market Implications

    June 27, 2024

    The Pros and Cons of Payday Loans: Understanding the Risks and Benefits

    March 27, 2024
  • World News

    HNA Group Chairman Chen Feng Gives Speech at 2015 WTTC Global Summit: China Sees Huge Tourism Cooperation Opportunities with Europe

    October 24, 2020

    Greyrock Direct Fuel Production(TM) Recognized by the World Bank as Most Advanced Technology for Gas-to-Liquids

    September 28, 2020

    DJI to Open Flagship Store in Hong Kong

    August 29, 2020

    Micreos Secures Euros 12 Million for New Products Containing Staphefekt; Alternative to Antibiotics Can Help Millions

    June 18, 2020

    NetEase Debuts New Publicity Video in Shibuya, Triggers Speculation in Japan Game Industry

    April 19, 2020
  • Technology
  • Sports
  • Money
  • Health
  • Life & Style
  • Shopping
Daily News
Home»Business»New Data Presented at WCCS Confirm High Long-term Efficacy of Picato® in Patients with Actinic Keratosis
Business

New Data Presented at WCCS Confirm High Long-term Efficacy of Picato® in Patients with Actinic Keratosis

AndrewBy AndrewSeptember 4, 2014No Comments7 Mins Read0 Views
Facebook Twitter Pinterest Telegram LinkedIn Tumblr Copy Link Email
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link

New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato(R) (ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased.[1] The data also confirm two treatment cycles of Picato(R) are well tolerated by patients.[2]

    These findings are significant as AK is a chronic disease.[1] The presence of underlying sub-clinical (invisible) lesions can lead to recurrence of original AKs and the development of new lesions over time[3], which normally require repeat treatment. The FIELD Study Repeat followed patients over a one-year-period, confirming both the short and in particular the long-term benefits when treating once or twice of Picato(R) – with an overall 50% complete clearance of all AK lesions after one year*.[1]

    Presenting the data at WCCS today, Professor Claus Garbe, Department of Dermatology, University Hospital Tübingen, Germany and Principal Investigator of the FIELD Repeat Study, commented: “AK is a very common precursor to non-melanoma skin cancer, which requires ongoing treatment. The new data from the FIELD Study Repeat validate Picato(R) as a well-tolerated field-directed therapy, suitable for the long-term treatment of actinic keratoses, showing an overall high complete clearance rate after one year.”

    The FIELD Study Repeat is part of the larger international FIELD Study Programme being run by LEO Pharma, designed in partnership with leading clinicians to investigate the potential broader role of Picato(R) in the management of AK.

    Additional data from the FIELD Study Programme was recently published in the Journal of Drugs in Dermatology (JDD)[4] with the long-term results of the FIELD Study 1, investigating the efficacy of Picato(R) as a field-directed therapy used sequentially following treatment with cryosurgery.[4]
Results show that combining lesion-specific cryosurgery with Picato(R) field therapy significantly improves the clearance of AK lesions, with an overall 30.5% complete clearance rate, compared to 18.5% with cryosurgery plus vehicle gel over a one year period.[4]

    This elevated efficacy results from enhancing the effect of cryosurgery with Picato(R) on the visible baseline lesions, and from a ‘field treatment effect’ of Picato(R) on sub-clinical lesions not visible at baseline (demonstrated by fewer patients experiencing new lesions when treated with Picato(R) compared to vehicle gel).[4] The data also confirm Picato(R) field therapy after cryosurgery is well tolerated.[4]

    Dr William Hanke, Founder and Medical Director, Dermatologic Surgery, Laser and Skin Center of Indiana, US, and FIELD Study 1 Principal investigator, added:
“The recently published 12 month data from FIELD Study 1 show sustained patient benefits of field treatment with Picato(R) in combination with cryosurgery. These data are now reinforced with evidence that repeat use of Picato(R) is efficacious and well tolerated over the same time period. Combined, these studies provide further evidence for the role of field treatment with Picato(R) in achieving long-term clearance of AK lesions.”

    Follow @LEOHealthySkin for the latest updates from #WCCS2014.

    * Patients treated twice with Picato(R) or treated once and remained clear at 8w, 26w and 44w, 50% were still clear at 12m (44.0%-56.1%, 95% CI)

    NOTES TO EDITORS

    1. About Picato(R) (ingenol mebutate gel)
    Picato(R) is a topical, field-directed therapy which is self-administered by the patient to the affected areas of the skin once a day for two or three consecutive days, depending on the treatment location.[5] Picato(R) has demonstrated efficacy in clearing actinic keratosis lesions on the face and scalp, as well as on the trunk and extremities, in a large clinical trial programme.[5]
Picato(R) was approved by the US Food and Drug Administration (FDA) in January 2012; by the Agência Nacional de Vigilância Sanitária (ANVISA) in Brazil in July 2012; by the Therapeutic Goods Administration (TGA) in Australia and the European Commission (EC) in Europe in November 2012, by Health Canada in January 2013 and by the Swiss Agency of Therapeutic Products (Swissmedic) in June 2013.

    2. About FIELD Study Repeat[1]
    The FIELD Study Repeat involved 450 patients across 5 countries globally, designed to explore the efficacy and tolerability of Picato(R) repeated treatment within the same area or ‘field’ on the face or scalp over a 12 month period. 

    3. About the FIELD Study 1[4]
    The FIELD Study 1 involved more than 300 patients across 35 US trial sites and explored the efficacy and safety profile of sequential treatment of AK on the face or scalp with cryosurgery followed by Picato(R), 0.015% treatment compared with cryosurgery followed by vehicle gel. 

    4. About actinic keratosis (AK)
    Actinic keratoses are common skin lesions which are often red and scaly.[6] The majority of lesions are caused by cumulative sun exposure in fair-skinned people.[7] AK is a precursor to non-melanoma skin cancer (NMSC).[8] The number of patients with actinic keratosis is rapidly growing, especially in Europe, the US and Australia.[9] Prevelance currently ranges from 11-25% in the Northern Hemisphere to 40-60% in the Southern Hemisphere.[7]

    5. About LEO Pharma
    Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company. LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. The company has its own sales forces in 61 countries and employs around 4,800 people worldwide. LEO Pharma is headquartered in Denmark and is wholly owned by the LEO Foundation.

    6. Picato(R) Abrev. SmPC
    Contact with the eyes should be avoided. Eye disorders such as eye pain, eyelid oedema and periorbital oedema should be expected to occur after accidental eye exposure of Picato(R). Picato(R) must not be ingested. Administration of Picato(R) is not recommended until the skin is healed from treatment with any previous medicinal product or surgical treatment and should not be applied to open wounds or damaged skin where the skin barrier is compromised. Picato(R) should not be used near the eyes, on the inside of the nostrils, on the inside of the ears or on the lips. Local skin responses such as erythema, flaking/scaling, and crusting should be expected to occur after cutaneous application of Picato(R). Due to the nature of the disease, excessive exposure to sunlight (including sunlamps and tanning beds) should be avoided or minimised. Lesions clinically atypical for actinic keratosis or suspicious for malignancy should be biopsied to determine appropriate treatment. There are no data from the use of ingenol mebutate gel in pregnant women. Risks to humans receiving cutaneous treatment with ingenol mebutate gel are considered unlikely as Picato(R) is not absorbed systemically. As a precautionary measure, it is preferable to avoid the use of Picato(R) during pregnancy. Actinic keratosis is not a condition generally seen within the paediatric population. The safety and efficacy of Picato(R) for actinic keratosis in patients less than 18 years of age have not been established. 

    7. References:
    1. Garbe C. Ingenol mebutate gel 0.015% repeat use for multiple actinic keratoses on face and scalp: a 12 month pahse 3 clinical study. Presented at the World Congress on Cancers of the Skin, Edinburgh, Scotland. 4 September 2014
    2. LP0041-22 Clinical Study Report EudraCT no. 2011-005018-13 01-Jul-2014 page 1,165
    3. Berman B et al. Cutis. 2012; 89:241-50
    4. Berman B et al. Journal of drugs in dermatology : JDD. 2014; 13:741-7
    5. Lebwohl M et al. N Eng J Med. 2012; 366:1010-9
    6. Goldberg L and Mamelak A. Journal of drugs in Dermatology. 2010; 9:1125-32
    7. Frost C et al. The British journal of dermatology. 1994; 142:722-6
    8. Sober A. Cancer. 1995; 75(2 Suppl):645-50
    9. Ulrich M et al. Expert Opinion. 2010; 15:545 – 55

    Global Media Contact
    Polly Lutter
    Global Communications Manager
    LEO Pharma A/S, Denmark
    polly.lutter@leo-pharma.com
    Tel: +44-(0)20-7300-6137

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Telegram Email Copy Link
Andrew

Related Posts

What Size Skip Do You Need for Your Project?

May 12, 2025

Introduction to Share CFDs: Understanding the Basics

December 2, 2024

Importance of Proper Disposal in Spray Foam Removal

August 26, 2024

Comments are closed.

Featured Posts

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Don't Miss!

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Top Posts

Importance of Proper Disposal in Spray Foam Removal

August 26, 202418 Views

Introduction to Share CFDs: Understanding the Basics

December 2, 202411 Views

PVC Windows and Doors still the most popular choice

October 12, 201211 Views

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 202510 Views
Don't Miss

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 20253 Mins Read10 Views

Swing trading offers a practical balance between day trading and long-term investing. It gives traders…

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Stay In Touch
  • Facebook
  • Twitter
  • Instagram
  • YouTube

Subscribe to Updates

Get the latest creative news from SmartMag about art & design.

About Us
About Us

Daily News blog provides you the latest news, guide and tips, related information and issues about the Automotive, Business, Technology, Sports, Life & Style, News Photography, and Shopping etc.

Facebook X (Twitter) Instagram
Our Picks

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025
Most Popular

Mark Ingram wins 2009 Heisman Trophy

December 15, 20090 Views

Dubai receives bailout from Abu Dhabi

December 15, 20090 Views

North Korean weapons seized in Thailand

December 15, 20090 Views
Daily News
  • Home
  • About
  • Contact
  • Privacy Policy
Copyright © 2019-2025. Daily News..

Type above and press Enter to search. Press Esc to cancel.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT